Highly Variable Drug Bioequivalence Could Be Shown Through Reference Scaling, Cmte. Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
Reference scaling may be an interim solution to demonstrating bioequivalence for highly variable drug products; in the future, FDA should create a decision tree that allows the bioequivalence range to adjust with the drug's variability, FDA's Pharmaceutical Science Advisory Committee says.